Lexeo Therapeutics(LXEO) - 2025 Q1 - Quarterly Results

Exhibit 99.1 Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights Announced positive interim data for LX2006 from Phase 1/2 studies in Friederich ataxia (FA) cardiomyopathy; frataxin expression and LVMI improvement exceeded co-primary target thresholds for planned registrational study LX2006 registrational study expected to begin by early 2026; commencing enrollment in prospective natural history study, CLARITY- FA, in Q2 2025 to serve as concurrent external control Pha ...